Antibiotic Resistance in Microbial Keratitis: Ten-Year Experience of Corneal Scrapes in the United Kingdom

Purpose To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Design Retrospective, observational case series. Participants Corneal scrapes over a 10-year period to December 2008 were identified using the local microbiology database, which provided cult...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 118; no. 11; pp. 2161 - 2165
Main Authors Shalchi, Zaid, MBBS, BSc, Gurbaxani, Avinash, MBBS, MRCS(Ed) (Ophth), Baker, Mark, PhD, FIBMS, Nash, James, FRCPath
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.11.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Design Retrospective, observational case series. Participants Corneal scrapes over a 10-year period to December 2008 were identified using the local microbiology database, which provided culture results and antibiotic sensitivity-resistance profiles. Testing Isolate sensitivity to chloramphenicol, cefuroxime, gentamicin, and ciprofloxacin was determined by microdilution using the Microscan System (Siemens Diagnostics, Dearfield, IL). Main Outcome Measures Isolates were graded as sensitive, intermediate, or resistant to the tested antibiotics, with minimal inhibitory concentrations interpreted against breakpoints from the Clinical and Laboratory Standards Institute. Results There were 476 scrapes from 440 patients (female, 57.6%; mean age, 53.5 years). All samples were cultured. Culture was positive in 163 samples (34.2%), growing 172 organisms. Bacterial keratitis accounted for 162 isolates (94.2%), of which 99 (61.1%) were gram-negative. There was a general increase in the number of gram-negative isolates with time ( P =0.003). In vitro testing showed widespread gram-negative resistance to chloramphenicol (74.1%), with reducing sensitivity over the study period ( P =0.004). There was 97.3% sensitivity to combination gentamicin and cefuroxime, and 94.4% sensitivity to ciprofloxacin. Ciprofloxacin resistance was found in 8 (17.0%) of 47 gram-positive isolates tested, with no trend toward increasing resistance. Conclusions This study has documented the highest levels of gram-negative keratitis in any open retrospective survey to date and highlights a trend of increasing gram-negative infection. We have demonstrated reducing chloramphenicol sensitivity, with high sensitivity to combination gentamicin and cefuroxime, as well as ciprofloxacin. Gram-positive fluoroquinolone resistance was higher than previously reported in the United Kingdom, but showed no evidence of increasing resistance. Second-generation fluoroquinolone monotherapy remains the recommended empirical treatment in microbial keratitis in the United Kingdom, and a change to fourth-generation compounds is not advised. Continued testing is essential to monitor for increasing resistance. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
AbstractList Purpose To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Design Retrospective, observational case series. Participants Corneal scrapes over a 10-year period to December 2008 were identified using the local microbiology database, which provided culture results and antibiotic sensitivity-resistance profiles. Testing Isolate sensitivity to chloramphenicol, cefuroxime, gentamicin, and ciprofloxacin was determined by microdilution using the Microscan System (Siemens Diagnostics, Dearfield, IL). Main Outcome Measures Isolates were graded as sensitive, intermediate, or resistant to the tested antibiotics, with minimal inhibitory concentrations interpreted against breakpoints from the Clinical and Laboratory Standards Institute. Results There were 476 scrapes from 440 patients (female, 57.6%; mean age, 53.5 years). All samples were cultured. Culture was positive in 163 samples (34.2%), growing 172 organisms. Bacterial keratitis accounted for 162 isolates (94.2%), of which 99 (61.1%) were gram-negative. There was a general increase in the number of gram-negative isolates with time ( P =0.003). In vitro testing showed widespread gram-negative resistance to chloramphenicol (74.1%), with reducing sensitivity over the study period ( P =0.004). There was 97.3% sensitivity to combination gentamicin and cefuroxime, and 94.4% sensitivity to ciprofloxacin. Ciprofloxacin resistance was found in 8 (17.0%) of 47 gram-positive isolates tested, with no trend toward increasing resistance. Conclusions This study has documented the highest levels of gram-negative keratitis in any open retrospective survey to date and highlights a trend of increasing gram-negative infection. We have demonstrated reducing chloramphenicol sensitivity, with high sensitivity to combination gentamicin and cefuroxime, as well as ciprofloxacin. Gram-positive fluoroquinolone resistance was higher than previously reported in the United Kingdom, but showed no evidence of increasing resistance. Second-generation fluoroquinolone monotherapy remains the recommended empirical treatment in microbial keratitis in the United Kingdom, and a change to fourth-generation compounds is not advised. Continued testing is essential to monitor for increasing resistance. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Retrospective, observational case series. Corneal scrapes over a 10-year period to December 2008 were identified using the local microbiology database, which provided culture results and antibiotic sensitivity-resistance profiles. Isolate sensitivity to chloramphenicol, cefuroxime, gentamicin, and ciprofloxacin was determined by microdilution using the Microscan System (Siemens Diagnostics, Dearfield, IL). Isolates were graded as sensitive, intermediate, or resistant to the tested antibiotics, with minimal inhibitory concentrations interpreted against breakpoints from the Clinical and Laboratory Standards Institute. There were 476 scrapes from 440 patients (female, 57.6%; mean age, 53.5 years). All samples were cultured. Culture was positive in 163 samples (34.2%), growing 172 organisms. Bacterial keratitis accounted for 162 isolates (94.2%), of which 99 (61.1%) were gram-negative. There was a general increase in the number of gram-negative isolates with time (P=0.003). In vitro testing showed widespread gram-negative resistance to chloramphenicol (74.1%), with reducing sensitivity over the study period (P=0.004). There was 97.3% sensitivity to combination gentamicin and cefuroxime, and 94.4% sensitivity to ciprofloxacin. Ciprofloxacin resistance was found in 8 (17.0%) of 47 gram-positive isolates tested, with no trend toward increasing resistance. This study has documented the highest levels of gram-negative keratitis in any open retrospective survey to date and highlights a trend of increasing gram-negative infection. We have demonstrated reducing chloramphenicol sensitivity, with high sensitivity to combination gentamicin and cefuroxime, as well as ciprofloxacin. Gram-positive fluoroquinolone resistance was higher than previously reported in the United Kingdom, but showed no evidence of increasing resistance. Second-generation fluoroquinolone monotherapy remains the recommended empirical treatment in microbial keratitis in the United Kingdom, and a change to fourth-generation compounds is not advised. Continued testing is essential to monitor for increasing resistance. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
PURPOSETo determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom.DESIGNRetrospective, observational case series.PARTICIPANTSCorneal scrapes over a 10-year period to December 2008 were identified using the local microbiology database, which provided culture results and antibiotic sensitivity-resistance profiles.TESTINGIsolate sensitivity to chloramphenicol, cefuroxime, gentamicin, and ciprofloxacin was determined by microdilution using the Microscan System (Siemens Diagnostics, Dearfield, IL).MAIN OUTCOME MEASURESIsolates were graded as sensitive, intermediate, or resistant to the tested antibiotics, with minimal inhibitory concentrations interpreted against breakpoints from the Clinical and Laboratory Standards Institute.RESULTSThere were 476 scrapes from 440 patients (female, 57.6%; mean age, 53.5 years). All samples were cultured. Culture was positive in 163 samples (34.2%), growing 172 organisms. Bacterial keratitis accounted for 162 isolates (94.2%), of which 99 (61.1%) were gram-negative. There was a general increase in the number of gram-negative isolates with time (P=0.003). In vitro testing showed widespread gram-negative resistance to chloramphenicol (74.1%), with reducing sensitivity over the study period (P=0.004). There was 97.3% sensitivity to combination gentamicin and cefuroxime, and 94.4% sensitivity to ciprofloxacin. Ciprofloxacin resistance was found in 8 (17.0%) of 47 gram-positive isolates tested, with no trend toward increasing resistance.CONCLUSIONSThis study has documented the highest levels of gram-negative keratitis in any open retrospective survey to date and highlights a trend of increasing gram-negative infection. We have demonstrated reducing chloramphenicol sensitivity, with high sensitivity to combination gentamicin and cefuroxime, as well as ciprofloxacin. Gram-positive fluoroquinolone resistance was higher than previously reported in the United Kingdom, but showed no evidence of increasing resistance. Second-generation fluoroquinolone monotherapy remains the recommended empirical treatment in microbial keratitis in the United Kingdom, and a change to fourth-generation compounds is not advised. Continued testing is essential to monitor for increasing resistance.FINANCIAL DISCLOSURE(S)The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Author Gurbaxani, Avinash, MBBS, MRCS(Ed) (Ophth)
Baker, Mark, PhD, FIBMS
Nash, James, FRCPath
Shalchi, Zaid, MBBS, BSc
Author_xml – sequence: 1
  fullname: Shalchi, Zaid, MBBS, BSc
– sequence: 2
  fullname: Gurbaxani, Avinash, MBBS, MRCS(Ed) (Ophth)
– sequence: 3
  fullname: Baker, Mark, PhD, FIBMS
– sequence: 4
  fullname: Nash, James, FRCPath
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24729550$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21764458$$D View this record in MEDLINE/PubMed
BookMark eNqFksFu1DAQhi1URLeFN0AoF8Qpy9hxnIQDUrUqLWoREl0OnCzHGbNesnZqexF9exx2AYkLJ1--f_7xpzkjJ847JOQ5hSUFKl5vl37apI1aMqB0CXwJjD4iC1rzruQNrU7IImO0FJzBKTmLcQsAQlT8CTlltBGc1-2CbC9csr31yeriE0Ybk3IaC-uKD1YH31s1FjcYVLLJxjfFGl35BVUoLn9MGCzOrDfFygeHmbzTQU0Y53jaYPHZ2YRDcWPd18HvnpLHRo0Rnx3fc7J-d7leXZe3H6_ery5uS11TlkqNbWf6tu7EUDe1EYapvgU2iEprRrUB0UOnQXTC0I5qDcZo3kPT9BX01FTn5NVh7BT8_R5jkjsbNY6jcuj3UXbAqop1HWSSH8j80RgDGjkFu1PhQVKQs2O5lQfHcnYsgcvsOMdeHAv2_Q6HP6HfUjPw8gioqNVoQlZq41-ON6yr67n_7YHDbOO7xSCj_qV0sAF1koO3_9vk3wF6tM7mzm_4gHHr98Fl05LKyCTIu_ke5nOgFIBD21Y_Aetesvc
CODEN OPHTDG
CitedBy_id crossref_primary_10_1016_j_exer_2021_108476
crossref_primary_10_1097_ICO_0000000000002830
crossref_primary_10_1097_ICO_0000000000000734
crossref_primary_10_1016_j_ajo_2014_09_021
crossref_primary_10_1371_journal_pone_0213103
crossref_primary_10_33321_cdi_2020_44_86
crossref_primary_10_1016_j_yoph_2012_03_041
crossref_primary_10_1186_s41182_023_00496_x
crossref_primary_10_3341_kjo_2022_0064
crossref_primary_10_1097_MD_0000000000011318
crossref_primary_10_3390_jcm10235671
crossref_primary_10_1186_s12886_020_1306_8
crossref_primary_10_1097_ICL_0000000000000993
crossref_primary_10_1371_journal_pone_0165223
crossref_primary_10_1007_s40135_013_0022_4
crossref_primary_10_3341_jkos_2021_62_4_447
crossref_primary_10_1071_HI15014
crossref_primary_10_1111_vop_12480
crossref_primary_10_1111_ceo_13672
crossref_primary_10_1097_ICO_0000000000000428
crossref_primary_10_1136_bjophthalmol_2018_312881
crossref_primary_10_1080_02713683_2023_2288803
crossref_primary_10_1097_ICO_0000000000003179
crossref_primary_10_1038_s41598_021_93172_1
crossref_primary_10_1136_bjophthalmol_2016_310026
crossref_primary_10_1016_j_jtos_2022_05_004
crossref_primary_10_1097_ICL_0b013e3182a3024e
crossref_primary_10_1097_ICO_0000000000001390
crossref_primary_10_4103_ijo_IJO_1438_22
crossref_primary_10_1016_j_preteyeres_2021_101031
crossref_primary_10_1111_aos_14789
crossref_primary_10_1136_bmjopen_2022_069338
crossref_primary_10_1016_j_jcjo_2014_12_013
crossref_primary_10_1111_ceo_13364
crossref_primary_10_1155_2012_831502
crossref_primary_10_1155_2015_769436
crossref_primary_10_3390_proteomes3040496
crossref_primary_10_4274_tjo_galenos_2021_98046
crossref_primary_10_1038_s41433_020_01378_w
crossref_primary_10_1136_bmjophth_2022_001002
crossref_primary_10_1097_ICO_0000000000000352
crossref_primary_10_1155_2013_369094
crossref_primary_10_3341_jkos_2021_62_11_1465
crossref_primary_10_1080_02713683_2018_1461907
crossref_primary_10_1016_j_pdpdt_2022_102717
crossref_primary_10_3341_jkos_2014_55_10_1432
crossref_primary_10_1038_eye_2015_250
crossref_primary_10_1136_bjophthalmol_2015_307371
crossref_primary_10_1097_ICL_0000000000000173
crossref_primary_10_1016_j_ophtha_2012_03_031
crossref_primary_10_1186_s12879_019_4418_0
crossref_primary_10_3389_fcimb_2023_1250257
crossref_primary_10_1016_j_jcjo_2022_08_012
crossref_primary_10_13181_mji_v24i3_1044
crossref_primary_10_1016_j_jcjo_2017_11_001
crossref_primary_10_1097_ICL_0000000000000298
crossref_primary_10_1016_j_jfo_2023_07_019
crossref_primary_10_18008_1816_5095_2023_1_17_23
crossref_primary_10_7883_yoken_JJID_2018_269
crossref_primary_10_1016_j_survophthal_2018_12_003
crossref_primary_10_1097_ICO_0000000000000844
crossref_primary_10_1155_2019_6328058
crossref_primary_10_2147_OPTH_S395877
crossref_primary_10_3390_jpm13030519
crossref_primary_10_1111_ceo_12723
crossref_primary_10_3341_jkos_2019_60_11_1027
crossref_primary_10_1177_0300060513505957
crossref_primary_10_3341_jkos_2024_65_3_181
crossref_primary_10_1136_bjophthalmol_2017_311751
crossref_primary_10_2174_2212796816666220419121948
crossref_primary_10_1016_j_ajo_2023_06_016
crossref_primary_10_1016_j_ophtha_2014_11_027
crossref_primary_10_3390_diagnostics12092095
crossref_primary_10_1097_ICL_0000000000000883
crossref_primary_10_1097_ICL_0b013e3182a3026b
Cites_doi 10.1016/S0161-6420(00)00179-2
10.1111/j.1442-9071.2004.00867.x
10.1016/S0161-6420(99)00717-4
10.1128/AAC.34.11.2050
10.1016/S0161-6420(99)00716-2
10.1038/eye.1998.221
10.1016/j.survophthal.2005.05.001
10.1016/j.ajo.2004.03.016
10.1097/00055735-200408000-00007
10.1016/S0161-6420(99)90008-8
10.1128/AAC.34.9.1862
10.1016/S0002-9394(03)00294-0
10.1016/S0161-6420(97)30009-8
10.1097/ICO.0b013e318156caf2
10.1136/bjo.84.7.687
10.1093/jac/26.suppl_F.165
10.1016/S0002-9394(03)00905-X
10.1136/bjo.87.7.834
10.1093/jac/37.2.243
10.1016/j.ajo.2006.06.030
10.1046/j.1469-0691.2003.00696.x
10.1097/01.icl.0000237825.98225.ca
10.1001/archopht.1995.01100100045026
10.1016/j.ophtha.2004.09.029
10.2165/00003088-199019060-00003
10.1016/j.survophthal.2005.05.005
ContentType Journal Article
Copyright American Academy of Ophthalmology
2011 American Academy of Ophthalmology
2015 INIST-CNRS
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: American Academy of Ophthalmology
– notice: 2011 American Academy of Ophthalmology
– notice: 2015 INIST-CNRS
– notice: Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.ophtha.2011.04.021
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-4713
EndPage 2165
ExternalDocumentID 10_1016_j_ophtha_2011_04_021
21764458
24729550
S0161642011004088
1_s2_0_S0161642011004088
Genre Journal Article
GeographicLocations United Kingdom
Europe
GroupedDBID -
08R
0R
1-
123
1B1
1P
1~5
29N
4.4
457
4G.
53G
55
5RE
5VS
7-5
71M
AAEDT
AAIAV
AALRI
AALRV
AAQFI
AAQQT
AAQXK
AAXUO
ABFLS
ABFRF
ABIID
ABLJU
ABMAC
ABOCM
ABPTK
ABQIS
ABWYI
ACGFO
ACGFS
ACIUM
ACNCT
ADPAM
AEFWE
AENEX
AEVXI
AFFNX
AFRHN
AFTJW
AGZHU
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
ALXNB
BELOY
C5W
CS3
DU5
EBS
EFJIC
EJD
F5P
FDB
FEDTE
FGOYB
FO
GBLVA
GJ
HVGLF
HZ
IHE
IPNFZ
J1W
K
K-O
KOM
L7B
M27
M41
MO0
N4W
N9A
NQ-
O9-
OF-
OPF
OQ
P2P
R2-
RIG
ROL
RPZ
SDG
SEL
SES
SSZ
UHS
UNMZH
UV1
WH7
X7M
XH2
XPP
Z5R
ZA5
ZGI
ZXP
---
--K
.1-
.55
.FO
.GJ
0R~
1P~
AAEDW
ABCQX
ABJNI
ADMUD
AHPSJ
AMRAJ
HZ~
OQ~
AAUGY
IQODW
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c512t-ce89fb8596d575f6f2ab802d63cc21cf06b09c0696f191cc0ffc4b077b30b1f3
ISSN 0161-6420
IngestDate Fri Aug 16 10:20:38 EDT 2024
Fri Aug 23 03:15:25 EDT 2024
Thu May 23 23:17:16 EDT 2024
Sun Oct 22 16:04:32 EDT 2023
Fri Feb 23 02:14:11 EST 2024
Thu Aug 18 18:35:47 EDT 2022
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Resistance
Eye disease
Antibiotic
Cornea
Keratitis
Keratopathy
Ophthalmology
Anterior segment disease
Language English
License CC BY 4.0
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c512t-ce89fb8596d575f6f2ab802d63cc21cf06b09c0696f191cc0ffc4b077b30b1f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 21764458
PQID 902332990
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_902332990
crossref_primary_10_1016_j_ophtha_2011_04_021
pubmed_primary_21764458
pascalfrancis_primary_24729550
elsevier_sciencedirect_doi_10_1016_j_ophtha_2011_04_021
elsevier_clinicalkeyesjournals_1_s2_0_S0161642011004088
PublicationCentury 2000
PublicationDate 2011-11-01
PublicationDateYYYYMMDD 2011-11-01
PublicationDate_xml – month: 11
  year: 2011
  text: 2011-11-01
  day: 01
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate Ophthalmology
PublicationYear 2011
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Schlech, Blondeau (bib22) 2005; 50
O'Brien, Maguire, Fink (bib3) 1995; 113
Chalita, Höfling-Lima, Paranhos (bib19) 2004; 137
Soussy, Nguyen, Goldstein (bib27) 2003; 9
Scheel, Lyon, Rosdahl (bib8) 1996; 37
Alexandrakis, Alfonso, Miller (bib10) 2000; 107
Daum, Schaberg, Terpenning (bib5) 1990; 34
Walker, Diaper, Bowman (bib18) 1998; 12
Raviglione, Boyle, Mariuz (bib6) 1990; 34
Ball (bib7) 1990; 26
Bourcier, Thomas, Borderie (bib17) 2003; 87
Alfonso, Crider (bib23) 2005; 50
Mah (bib2) 2004; 15
Rhee, Kowalski, Romanowski (bib26) 2004; 138
Solomon, Donnenfeld, Perry (bib24) 2005; 112
Kotlus, Wymbs, Vellozzi, Udell (bib20) 2006; 142
Garg, Sharma, Rao (bib21) 1999; 106
Goldstein, Kowalski, Gordon (bib9) 1999; 106
Green, Apel, Stapleton (bib15) 2008; 27
Rajpal, Hall, Long, Wells (bib16) 2007; 120
(bib1) 1997; 104
Hall, McKellar (bib14) 2004; 32
Kunimoto, Sharma, Garg, Rao (bib11) 1999; 106
Kowalski, Dhaliwal, Karenchak (bib25) 2003; 136
Tuft, Matheson (bib12) 2000; 84
Vance-Bryan, Guay, Rotschafer (bib4) 1990; 19
Toshida, Kogure, Inoue, Murakami (bib13) 2007; 33
Kowalski (10.1016/j.ophtha.2011.04.021_bib25) 2003; 136
Hall (10.1016/j.ophtha.2011.04.021_bib14) 2004; 32
Daum (10.1016/j.ophtha.2011.04.021_bib5) 1990; 34
Ball (10.1016/j.ophtha.2011.04.021_bib7) 1990; 26
Toshida (10.1016/j.ophtha.2011.04.021_bib13) 2007; 33
Soussy (10.1016/j.ophtha.2011.04.021_bib27) 2003; 9
Goldstein (10.1016/j.ophtha.2011.04.021_bib9) 1999; 106
Chalita (10.1016/j.ophtha.2011.04.021_bib19) 2004; 137
(10.1016/j.ophtha.2011.04.021_bib1) 1997; 104
Green (10.1016/j.ophtha.2011.04.021_bib15) 2008; 27
Kunimoto (10.1016/j.ophtha.2011.04.021_bib11) 1999; 106
Rhee (10.1016/j.ophtha.2011.04.021_bib26) 2004; 138
Bourcier (10.1016/j.ophtha.2011.04.021_bib17) 2003; 87
Walker (10.1016/j.ophtha.2011.04.021_bib18) 1998; 12
O'Brien (10.1016/j.ophtha.2011.04.021_bib3) 1995; 113
Solomon (10.1016/j.ophtha.2011.04.021_bib24) 2005; 112
Alexandrakis (10.1016/j.ophtha.2011.04.021_bib10) 2000; 107
Tuft (10.1016/j.ophtha.2011.04.021_bib12) 2000; 84
Garg (10.1016/j.ophtha.2011.04.021_bib21) 1999; 106
Raviglione (10.1016/j.ophtha.2011.04.021_bib6) 1990; 34
Scheel (10.1016/j.ophtha.2011.04.021_bib8) 1996; 37
Alfonso (10.1016/j.ophtha.2011.04.021_bib23) 2005; 50
Mah (10.1016/j.ophtha.2011.04.021_bib2) 2004; 15
Schlech (10.1016/j.ophtha.2011.04.021_bib22) 2005; 50
Vance-Bryan (10.1016/j.ophtha.2011.04.021_bib4) 1990; 19
Kotlus (10.1016/j.ophtha.2011.04.021_bib20) 2006; 142
Rajpal (10.1016/j.ophtha.2011.04.021_bib16) 2007; 120
References_xml – volume: 34
  start-page: 2050
  year: 1990
  end-page: 2054
  ident: bib6
  article-title: Ciprofloxacin-resistant methicillin-resistant
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Mariuz
– volume: 138
  start-page: 226
  year: 2004
  end-page: 230
  ident: bib26
  article-title: A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Romanowski
– volume: 113
  start-page: 1257
  year: 1995
  end-page: 1265
  ident: bib3
  article-title: Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group
  publication-title: Arch Ophthalmol
  contributor:
    fullname: Fink
– volume: 120
  start-page: U2682
  year: 2007
  ident: bib16
  article-title: Five-year experience of corneal scrapes at Wellington Eye Department, New Zealand
  publication-title: N Z Med J
  contributor:
    fullname: Wells
– volume: 9
  start-page: 997
  year: 2003
  end-page: 1005
  ident: bib27
  article-title: In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study
  publication-title: Clin Microbiol Infect
  contributor:
    fullname: Goldstein
– volume: 19
  start-page: 434
  year: 1990
  end-page: 461
  ident: bib4
  article-title: Clinical pharmacokinetics of ciprofloxacin
  publication-title: Clin Pharmacokinet
  contributor:
    fullname: Rotschafer
– volume: 15
  start-page: 316
  year: 2004
  end-page: 320
  ident: bib2
  article-title: Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections
  publication-title: Curr Opin Ophthalmol
  contributor:
    fullname: Mah
– volume: 34
  start-page: 1862
  year: 1990
  end-page: 1863
  ident: bib5
  article-title: Increasing resistance of
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Terpenning
– volume: 84
  start-page: 687
  year: 2000
  end-page: 691
  ident: bib12
  article-title: In vitro antibiotic resistance in bacterial keratitis in London
  publication-title: Br J Ophthalmol
  contributor:
    fullname: Matheson
– volume: 106
  start-page: 1319
  year: 1999
  end-page: 1323
  ident: bib21
  article-title: Ciprofloxacin-resistant Pseudomonas keratitis
  publication-title: Ophthalmology
  contributor:
    fullname: Rao
– volume: 137
  start-page: 43
  year: 2004
  end-page: 51
  ident: bib19
  article-title: Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Paranhos
– volume: 32
  start-page: 478
  year: 2004
  end-page: 481
  ident: bib14
  article-title: Bacterial keratitis in Christchurch, New Zealand, 1997-2001
  publication-title: Clin Experiment Ophthalmol
  contributor:
    fullname: McKellar
– volume: 37
  start-page: 243
  year: 1996
  end-page: 251
  ident: bib8
  article-title: In-vitro susceptibility of isolates of methicillin-resistant
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Rosdahl
– volume: 50
  start-page: S64
  year: 2005
  end-page: S67
  ident: bib22
  article-title: Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)
  publication-title: Surv Ophthalmol
  contributor:
    fullname: Blondeau
– volume: 106
  start-page: 1313
  year: 1999
  end-page: 1318
  ident: bib9
  article-title: Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review
  publication-title: Ophthalmology
  contributor:
    fullname: Gordon
– volume: 12
  start-page: 875
  year: 1998
  end-page: 879
  ident: bib18
  article-title: Lack of evidence for systemic toxicity following topical chloramphenicol use
  publication-title: Eye (Lond)
  contributor:
    fullname: Bowman
– volume: 106
  start-page: 80
  year: 1999
  end-page: 85
  ident: bib11
  article-title: In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: emerging resistance
  publication-title: Ophthalmology
  contributor:
    fullname: Rao
– volume: 50
  start-page: S1
  year: 2005
  end-page: S6
  ident: bib23
  article-title: Ophthalmic infections and their anti-infective challenges
  publication-title: Surv Ophthalmol
  contributor:
    fullname: Crider
– volume: 33
  start-page: 70
  year: 2007
  end-page: 73
  ident: bib13
  article-title: Trends in microbial keratitis in Japan
  publication-title: Eye Contact Lens
  contributor:
    fullname: Murakami
– volume: 136
  start-page: 500
  year: 2003
  end-page: 505
  ident: bib25
  article-title: Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Karenchak
– volume: 142
  start-page: 726
  year: 2006
  end-page: 729
  ident: bib20
  article-title: In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Udell
– volume: 104
  start-page: 1902
  year: 1997
  end-page: 1909
  ident: bib1
  article-title: Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy
  publication-title: Ophthalmology
– volume: 27
  start-page: 22
  year: 2008
  end-page: 27
  ident: bib15
  article-title: Risk factors and causative organisms in microbial keratitis
  publication-title: Cornea
  contributor:
    fullname: Stapleton
– volume: 107
  start-page: 1497
  year: 2000
  end-page: 1502
  ident: bib10
  article-title: Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones
  publication-title: Ophthalmology
  contributor:
    fullname: Miller
– volume: 26
  start-page: 165
  year: 1990
  end-page: 179
  ident: bib7
  article-title: Emergent resistance to ciprofloxacin amongst
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Ball
– volume: 87
  start-page: 834
  year: 2003
  end-page: 838
  ident: bib17
  article-title: Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases
  publication-title: Br J Ophthalmol
  contributor:
    fullname: Borderie
– volume: 112
  start-page: 466
  year: 2005
  end-page: 469
  ident: bib24
  article-title: Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor
  publication-title: Ophthalmology
  contributor:
    fullname: Perry
– volume: 107
  start-page: 1497
  year: 2000
  ident: 10.1016/j.ophtha.2011.04.021_bib10
  article-title: Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(00)00179-2
  contributor:
    fullname: Alexandrakis
– volume: 32
  start-page: 478
  year: 2004
  ident: 10.1016/j.ophtha.2011.04.021_bib14
  article-title: Bacterial keratitis in Christchurch, New Zealand, 1997-2001
  publication-title: Clin Experiment Ophthalmol
  doi: 10.1111/j.1442-9071.2004.00867.x
  contributor:
    fullname: Hall
– volume: 106
  start-page: 1319
  year: 1999
  ident: 10.1016/j.ophtha.2011.04.021_bib21
  article-title: Ciprofloxacin-resistant Pseudomonas keratitis
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(99)00717-4
  contributor:
    fullname: Garg
– volume: 34
  start-page: 2050
  year: 1990
  ident: 10.1016/j.ophtha.2011.04.021_bib6
  article-title: Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.34.11.2050
  contributor:
    fullname: Raviglione
– volume: 106
  start-page: 1313
  year: 1999
  ident: 10.1016/j.ophtha.2011.04.021_bib9
  article-title: Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(99)00716-2
  contributor:
    fullname: Goldstein
– volume: 12
  start-page: 875
  year: 1998
  ident: 10.1016/j.ophtha.2011.04.021_bib18
  article-title: Lack of evidence for systemic toxicity following topical chloramphenicol use
  publication-title: Eye (Lond)
  doi: 10.1038/eye.1998.221
  contributor:
    fullname: Walker
– volume: 50
  start-page: S1
  issue: Suppl
  year: 2005
  ident: 10.1016/j.ophtha.2011.04.021_bib23
  article-title: Ophthalmic infections and their anti-infective challenges
  publication-title: Surv Ophthalmol
  doi: 10.1016/j.survophthal.2005.05.001
  contributor:
    fullname: Alfonso
– volume: 138
  start-page: 226
  year: 2004
  ident: 10.1016/j.ophtha.2011.04.021_bib26
  article-title: A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2004.03.016
  contributor:
    fullname: Rhee
– volume: 15
  start-page: 316
  year: 2004
  ident: 10.1016/j.ophtha.2011.04.021_bib2
  article-title: Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections
  publication-title: Curr Opin Ophthalmol
  doi: 10.1097/00055735-200408000-00007
  contributor:
    fullname: Mah
– volume: 106
  start-page: 80
  year: 1999
  ident: 10.1016/j.ophtha.2011.04.021_bib11
  article-title: In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: emerging resistance
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(99)90008-8
  contributor:
    fullname: Kunimoto
– volume: 34
  start-page: 1862
  year: 1990
  ident: 10.1016/j.ophtha.2011.04.021_bib5
  article-title: Increasing resistance of Staphylococcus aureus to ciprofloxacin
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.34.9.1862
  contributor:
    fullname: Daum
– volume: 136
  start-page: 500
  year: 2003
  ident: 10.1016/j.ophtha.2011.04.021_bib25
  article-title: Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates
  publication-title: Am J Ophthalmol
  doi: 10.1016/S0002-9394(03)00294-0
  contributor:
    fullname: Kowalski
– volume: 104
  start-page: 1902
  year: 1997
  ident: 10.1016/j.ophtha.2011.04.021_bib1
  article-title: Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy
  publication-title: Ophthalmology
  doi: 10.1016/S0161-6420(97)30009-8
– volume: 27
  start-page: 22
  year: 2008
  ident: 10.1016/j.ophtha.2011.04.021_bib15
  article-title: Risk factors and causative organisms in microbial keratitis
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e318156caf2
  contributor:
    fullname: Green
– volume: 84
  start-page: 687
  year: 2000
  ident: 10.1016/j.ophtha.2011.04.021_bib12
  article-title: In vitro antibiotic resistance in bacterial keratitis in London
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.84.7.687
  contributor:
    fullname: Tuft
– volume: 26
  start-page: 165
  issue: Suppl
  year: 1990
  ident: 10.1016/j.ophtha.2011.04.021_bib7
  article-title: Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/26.suppl_F.165
  contributor:
    fullname: Ball
– volume: 137
  start-page: 43
  year: 2004
  ident: 10.1016/j.ophtha.2011.04.021_bib19
  article-title: Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years
  publication-title: Am J Ophthalmol
  doi: 10.1016/S0002-9394(03)00905-X
  contributor:
    fullname: Chalita
– volume: 87
  start-page: 834
  year: 2003
  ident: 10.1016/j.ophtha.2011.04.021_bib17
  article-title: Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.87.7.834
  contributor:
    fullname: Bourcier
– volume: 37
  start-page: 243
  year: 1996
  ident: 10.1016/j.ophtha.2011.04.021_bib8
  article-title: In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/37.2.243
  contributor:
    fullname: Scheel
– volume: 142
  start-page: 726
  year: 2006
  ident: 10.1016/j.ophtha.2011.04.021_bib20
  article-title: In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2006.06.030
  contributor:
    fullname: Kotlus
– volume: 9
  start-page: 997
  year: 2003
  ident: 10.1016/j.ophtha.2011.04.021_bib27
  article-title: In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study
  publication-title: Clin Microbiol Infect
  doi: 10.1046/j.1469-0691.2003.00696.x
  contributor:
    fullname: Soussy
– volume: 33
  start-page: 70
  year: 2007
  ident: 10.1016/j.ophtha.2011.04.021_bib13
  article-title: Trends in microbial keratitis in Japan
  publication-title: Eye Contact Lens
  doi: 10.1097/01.icl.0000237825.98225.ca
  contributor:
    fullname: Toshida
– volume: 113
  start-page: 1257
  year: 1995
  ident: 10.1016/j.ophtha.2011.04.021_bib3
  article-title: Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis: report from the Bacterial Keratitis Study Research Group
  publication-title: Arch Ophthalmol
  doi: 10.1001/archopht.1995.01100100045026
  contributor:
    fullname: O'Brien
– volume: 112
  start-page: 466
  year: 2005
  ident: 10.1016/j.ophtha.2011.04.021_bib24
  article-title: Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2004.09.029
  contributor:
    fullname: Solomon
– volume: 120
  start-page: U2682
  year: 2007
  ident: 10.1016/j.ophtha.2011.04.021_bib16
  article-title: Five-year experience of corneal scrapes at Wellington Eye Department, New Zealand
  publication-title: N Z Med J
  contributor:
    fullname: Rajpal
– volume: 19
  start-page: 434
  year: 1990
  ident: 10.1016/j.ophtha.2011.04.021_bib4
  article-title: Clinical pharmacokinetics of ciprofloxacin
  publication-title: Clin Pharmacokinet
  doi: 10.2165/00003088-199019060-00003
  contributor:
    fullname: Vance-Bryan
– volume: 50
  start-page: S64
  issue: Suppl
  year: 2005
  ident: 10.1016/j.ophtha.2011.04.021_bib22
  article-title: Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX)
  publication-title: Surv Ophthalmol
  doi: 10.1016/j.survophthal.2005.05.005
  contributor:
    fullname: Schlech
SSID ssj0006634
Score 2.394258
Snippet Purpose To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Design Retrospective, observational case series....
To determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom. Retrospective, observational case series. Corneal scrapes...
PURPOSETo determine the scale of antibiotic resistance in microbial keratitis in East Kent, United Kingdom.DESIGNRetrospective, observational case...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 2161
SubjectTerms Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - pharmacology
Bacteria - drug effects
Bacteria - isolation & purification
Bacteriological Techniques
Biological and medical sciences
Cefuroxime - pharmacology
Ciprofloxacin - pharmacology
Cornea - microbiology
Corneal Ulcer - drug therapy
Corneal Ulcer - epidemiology
Corneal Ulcer - microbiology
Diseases of cornea, anterior segment and sclera
Drug Resistance, Bacterial
Eye Infections, Bacterial - drug therapy
Eye Infections, Bacterial - epidemiology
Eye Infections, Bacterial - microbiology
Female
Gentamicins - pharmacology
Humans
Male
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Miscellaneous
Ophthalmology
Retrospective Studies
United Kingdom - epidemiology
Title Antibiotic Resistance in Microbial Keratitis: Ten-Year Experience of Corneal Scrapes in the United Kingdom
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0161642011004088
https://dx.doi.org/10.1016/j.ophtha.2011.04.021
https://www.ncbi.nlm.nih.gov/pubmed/21764458
https://search.proquest.com/docview/902332990
Volume 118
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLaqTUJICHFfuUx-4DVVrnaCxEM2AYWyIm2dKE9W7CRaK3CqJeWBf8U_5Di2kxQ2DXiJ2lS51Ofzufk7xwi9pH5OApoXTk4j7oRZyJ0scQOHquZxpcuT2FPFySdzMj0PPyyj5Wj0c8Ba2jZ8In5cWVfyP1KFcyBXVSX7D5Ltbgon4DPIF44gYTj-lYxTqSo-qqYlw9fKE1TTdCUVGV71V4Lhn6mmyapvkc6jS-eL6tzTNzhu6RjVpSzariCqFKu21EfjjqpdT3L98taL_bS5aC6yr990_6Y2CWH23dJMfCkngwzD2TT9eDx93y6DZJZAv3397vz0KF2m8_aH9PtKZnWXmj5KZ5qhMSwlmqdn047YO8xWKLrcTrbCltEMM5rEcyAI0oszhdHCYeKA1Qx21HSvp7e2VqXTurqhu7Hg8DW60jroRMV6UrWjZPq3hhPX93praBkAvxnJjrrohxCORCpLtO_TJIJ4fz-dnX6edeYfXDjTUF7_L1uv2ZIK_3zydf7QnU1Wwywt9fYq18c_rR-0uIfumgAGpxqN99GokA_QrRND0XiI1j0ocQ9KvJK4AyXuQPkKW0jiHpK4KrGBJDaQVJcDJLGGJDaQfIQWb98sjqeO2dDDEeBXNo4o4qTkcZSQHKKEkpR-xmNXaQshfE-ULuFuIlySkNJLPCHcshQhdynlgcu9MniM9mQliwOE44JSknFCIh9C3DznQRhHRFCRhGEMdmuMHDuqbKPbtjDLZ1wzLQWmpMDckIEUxojaoWe2JBmMaFGb2V4zj9U-cxUZknhKrG2rRTDRwyuN06qdUQaou-GZhzsy7l7UQmyMsBU6A6WvVvIyWVTbmiXgaQfKkRyjJxoM_cUehRAnip_edPdn6HY_QZ-jveZyW7wAB7vhhwbSvwC16c3M
link.rule.ids 315,786,790,27957,27958
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibiotic+Resistance+in+Microbial+Keratitis%3A+Ten-Year+Experience+of+Corneal+Scrapes+in+the+United+Kingdom&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=SHALCHI%2C+Zaid&rft.au=GURBAXANI%2C+Avinash&rft.au=BAKER%2C+Mark&rft.au=NASH%2C+James&rft.date=2011-11-01&rft.pub=Elsevier&rft.issn=0161-6420&rft.eissn=1549-4713&rft.volume=118&rft.issue=11&rft.spage=2161&rft.epage=2165&rft_id=info:doi/10.1016%2Fj.ophtha.2011.04.021&rft.externalDBID=n%2Fa&rft.externalDocID=24729550
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642011X00106%2Fcov150h.gif